Biodesix, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Biodesix, Inc. Biodesix, Inc. (Nasdaq: BDSX) provides blood-based molecular diagnostic testing and development services focused on lung disease and oncology. Founded in 2005 and headquartered in Louisville, Colorado, the company operates primarily in the United States through CLIA-certified laboratories, offering diagnostic solutions that integrate genomics, proteomics, transcriptomics, and radiomics via its proprietary Diagnostic Cortex AI platform. Its core products include the Nodify Lung portfolio with Nodify XL2 and Nodify CDT tests for lung nodule malignancy risk assessment; the IQLung strategy encompassing GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests for advanced non-small cell lung cancer therapy guidance; and biopharmaceutical services such as companion diagnostic development, clinical trial testing, biomarker discovery, and regulatory support. Biodesix serves pulmonologists, thoracic surgeons, oncologists, and biopharma clients, emphasizing non-invasive blood tests to enable personalized treatment decisions and reduce unnecessary procedures. Recent developments include an expanded partnership with Bio-Rad Laboratories in October 2025 to develop and validate Droplet Digital PCR assays, notably the ddPLEX ESR1 mutation detection assay for advanced breast cancer on the QX600 platform; designation as a Thermo Fisher Scientific Center of Excellence for NGS diagnostics in August 2025; a one-for-twenty reverse stock split in September 2025; and a $55 million oversubscribed common stock and private placement financing in April 2024 to support commercial expansion, R&D, and product pipeline advancement.
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade
Biodesix to Participate in Upcoming Investor Conferences
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
Biodesix Announces First Quarter 2026 Results and Highlights
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
Comparing Biodesix (NASDAQ:BDSX) & Bausch + Lomb (NYSE:BLCO)
Biodesix Recognized as a Top Workplace for Third Consecutive Year
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates